Abstract OBJECTIVES: We evaluated the clinical benefit of segmentectomy for patients with cT1bN0M0 lung cancer.
INTRODUCTION
Treatment of early-stage lung cancer primarily involves surgical approaches, with patients undergoing either lobectomy or segmentectomy. The relative benefit of lobectomy versus segmentectomy, or sub-lobar resection, as a standard surgical approach to treating non-small-cell lung cancer is yet to be established. In the only prospective randomized, controlled trial comparing sublobar resection versus lobectomy for clinical stage T1N0M0 nonsmall-cell lung cancer, the Lung Cancer Study Group reported that a significantly higher local recurrence rate was observed in the sub-lobar resection group than in the lobectomy group [1] . These results established lobectomy with systemic lymph node dissection as the standard surgical procedure for early-stage lung cancer. However, recent advances in radiology and application of computed tomography (CT) to patient screening have now made it possible to detect small-sized lung cancers [2] , allowing for segmentectomy to again be considered as an alternative surgical procedure in these instances. Some researchers have reported a favourable outcome with segmentectomy over lobectomy for small-sized peripheral lung cancers in retrospective studies [3] [4] [5] [6] [7] [8] [9] [10] , but others have reported inferior oncological outcomes of segmentectomy to those of lobectomy [11] [12] [13] . Therefore, the issue of whether to treat small-sized peripheral cancers with lobectomy or segmentectomy remains controversial. To address this controversy, a phase III clinical trial comparing lobectomy and segmentectomy for patients with (cT1a) peripheral lung cancer, with tumour sizes up to 20 mm, is in progress in the United States (CALGB 140503) and Japan ( JCOG0802/WJOG4607L). Contrary to the abundant data on segmentectomy for patients with cT1aN0M0 lung cancer, there are few reports of segmentectomy for patients with cT1bN0M0 lung cancer. In this study, we evaluated the benefit of patients with cT1bN0M0 lung adenocarcinoma and squamous cell carcinoma by comparing oncological outcomes of segmentectomy versus lobectomy. Moreover, we investigated the association between surgical outcomes and the presence of pathological invasion. The purpose of this study was to review our experience with and evaluate the clinical benefit of segmentectomy for patients with cT1bN0M0 lung cancer.
MATERIALS AND METHODS

Patient selection
We retrospectively reviewed the medical records of 1695 consecutive patients who underwent resection for lung cancer at Hyogo Cancer Center between 1 January 1994 and 31 December 2005. We included the patients who satisfied the following criteria: (i) CT tumour size was between 21 and 30 mm with no sign of lymph node metastasis or distant metastasis (cT1bN0M0); (ii) tumour was pathologically confirmed to be adenocarcinoma or squamous cell carcinoma; (iii) tumour was not located in the right middle lobe; (iv) there was no synchronous or metachronous lung cancer; (v) lobectomy or segmentectomy with mediastinal lymphadenectomy was performed (sleeve lobectomy was excluded); (vi) complete resection was confirmed pathologically; (vii) general medical condition and lung function were able to tolerate lobectomy. We analysed 178 eligible patients. Contrast-enhanced CT was performed to evaluate the entire lung for preoperative staging. Only a few patients underwent positron emission tomography CT (PET-CT) scanning because the majority of these procedures were performed before PET-CT scan was introduced in our institution. Staging was designated by tumour, node, metastasis (TNM) classification according to the 7th edition of the American Joint Committee on Cancer Staging Manual and the Revised International System for staging lung cancer. Two expert pathologists evaluated the histopathology of all cases. After fixing the surgical specimens with 10% formalin and embedding them in paraffin, the serial sections were stained with haematoxylin and eosin and Elastica van Gieson to identify elastic tissue. The presence of vascular invasion was determined by identifying intravascular tumour cells surrounded by elastic fibres. The presence of lymphatic permeation was determined by identifying tumour cells floating in lymphatic vessels with no supporting smooth muscles or elastic fibres. We defined pathological invasion as the presence of vascular invasion or lymphatic permeation of the tumour. This was a non-randomized retrospective study, and candidates for segmentectomy were selected according to the responsible surgeons' judgement with regard to resectability and adequate surgical margins. After receiving a thorough explanation of both surgical procedures, patients selected their preferred surgical method. Our institutional review board approved the database used in this retrospective analysis, and written informed consent was obtained from all patients.
Surgical procedure of segmentectomy
The surgical procedure of segmentectomy was performed as follows. After the corresponding segmental bronchus was isolated, every lobe was temporarily inflated. The corresponding segmental bronchus was then tied to keep the segment inflated, and the other segment was deflated naturally. The line between the inflated lung and the collapsed lung indicated the intersegmental plane. The segment was cut along the line using stapling or electrocautery. This type of operation was reported as 'extended segmentectomy' by Tsubota et al. [3, 14] . During surgery, the surgeon was obliged to corroborate that the tumour and required lymph nodes had been completely removed and proved to be negative for involvement by frozen-section examination. Surgical margins were routinely confirmed by dividing the resected specimens during the surgery. We defined that adequate surgical margins for segmentectomy were greater than the size of tumour. If there were signs of lymph node metastasis, or adequate surgical margins were not confirmed, the planned segmentectomy was then converted to lobectomy.
Patient follow-up
All patients were evaluated postoperatively at 3-month intervals for 2 years, at 6-month intervals for the subsequent 3 years and then once a year thereafter. Follow-up examinations included chest radiographs, CT scans, haematological and biochemical analyses, including tumour markers, along with periodic clinical follow-up.
End-points and statistical analyses
The end-points of this retrospective study were overall survival (OS) and recurrence-free survival (RFS). Local recurrence was defined as any recurrence within the same lung, ipsilateral lymph nodes or pulmonary hilum. Distant recurrence was defined as any recurrence other than local recurrence. Statistical analyses were carried out using JMP 9 software (SAS Institute, Cary, NC). Student's t-test and the χ 2 test were performed to assess the significance of the differences in age, sex, smoking status, surgical procedure and pathological stage ( p-stage) between patients who underwent lobectomy and segmentectomy. Survival was calculated according to the Kaplan-Meier method, and differences in the distributions were evaluated by the log-rank test. The threshold for statistical significance was set at P < 0.05.
RESULTS
Segmentectomy was scheduled in 37 patients according to the responsible surgeons' judgement regarding resectability and adequate surgical margins using a segmental approach. Of these patients, 6 patients' procedures were converted to lobectomy during surgery. The reasons for conversion were surgical N1 or N2 in 3 patients and insufficient surgical margins in 3 patients. In total, segmentectomy was performed in 31 patients and lobectomy was performed in 147 patients (Fig. 1 ). There were no perioperative deaths. The median follow-up period was 90.4 and 100.4 months in patients who underwent lobectomy and segmentectomy. Clinicopathological characteristics of the 178 patients are given in Table 1 . There were no significant differences in age, gender, smoking status and lung function. Adjuvant chemotherapy was administered to 26 (18%) of the 147 patients who underwent lobectomy, and 0 (0%) of the 31 patients who underwent segmentectomy (P = 0.01). There were no significant differences in pathological tumour size and pathological stage. Adenocarcinoma histology was more common among the patients who underwent lobectomy (P = 0.10). The rates of pleural invasion and vascular invasion were similar between the patients who underwent lobectomy and segmentectomy; however, the rate of lymphatic permeation was higher in the patients who underwent lobectomy (P = 0.05).
All resected lobe and segments are given in Table 2 . In patients who underwent segmentectomy, more than half (54.8%) underwent left s1 + 2 + 3 segmentectomy. Figures 2A and B show the OS and RFS of the patients who underwent lobectomy and segmentectomy. There was no significant difference in either OS or RFS in patients who underwent lobectomy versus segmentectomy (5-year OS: 81.6 and 77.4%, respectively; P = 0.73; 5-year RFS: 71.4 and 74.2%, respectively; P = 0.79).
To more strictly adjust for patients' pathological background in the analysis, we then selected only pathologically confirmed pN0 (no lymph node metastasis) patients and divided them into two groups according to pathological invasiveness. Among pN0 patients without pathological invasion, there was no difference in OS or RFS between patients who underwent lobectomy and segmentectomy (5-year OS: 89.9 and 88.9%, respectively; P = 0.80; Fig. 3A ; 5-year RFS: 84.1 and 88.9%, respectively; P = 0.93; Fig. 3B ). In contrast, among pN0 patients with pathological invasion, greater OS and RFS were observed in patients who underwent lobectomy rather than in those who underwent segmentectomy (5-year OS: 80.9 and 54.6%, respectively; P = 0.19; Fig. 3C ; 5-year RFS: 70.2 and 45.5%, respectively; P = 0.28; Fig. 3D ).
Initial recurrence sites are given in Table 3 . Among pN0 patients without pathological invasion, there were no differences in the recurrence rate or initial recurrence site between lobectomy and segmentectomy. However, among pN0 patients with pathological invasion, a significantly higher rate of local and local + distant recurrence was observed in patients who underwent segmentectomy rather than lobectomy (45 and 15%, respectively; P = 0.02).
DISCUSSION
The present study demonstrated similar long-term outcomes of lobectomy and segmentectomy for cT1bN0M0 lung adenocarcinoma and squamous cell carcinoma. This study had a strong selection bias because the candidates for segmentectomy were selected according to the responsible surgeons' judgement, and patients who were scheduled for segmentectomy may have been switched to receive lobectomy if lymph node metastasis was proved by intraoperative rapid diagnosis. To minimize these kinds of biases, we selected only pN0 patients and divided them into two groups according to the presence of pathological invasion. As shown in Fig. 3C and D, there was a tendency that the outcomes of segmentectomy were inferior to those of lobectomy, and significantly higher rates of local and local + distant recurrence were observed in the patients with pathological invasion who underwent segmentectomy. From these results, we considered that the presence of pathological invasion had a strong relationship with the outcomes of lobectomy and segmentectomy. Koike et al.
reported that pathological invasion and wedge resection were closely associated with the loco-regional recurrence of cT1aN0M0 lung non-small-cell lung cancer [15] . These results showed that even in cT1a cases, pathological invasion itself was associated with loco-regional recurrence. Therefore, patients with pathological invasion may need greater surgical margins and lymph node dissection than patients without pathological invasion. As it was obvious that lobectomy permitted better surgical margins and easier lymph node dissection than sub-lobar resection, segmentectomy for patients with cT1b tumours with pathological invasion may be inadequate to eradicate tumour cells, and these facts may have affected the oncological outcomes in this study.
On the other hand, segmentectomy may be performed for patients with T1b tumours with the same potential for cure as with lobectomy if pathological non-invasiveness could be accurately predicted before surgery. Several researchers reported the relationships between pathological invasiveness and radiological examinations. Suzuki et al. reported that the pathological invasiveness of cT1a lung adenocarcinoma was accurately predicted by consolidation to tumour size ratio measured by high-resolution computed tomography (HRCT) [16] . They reported that radiological non-invasive peripheral lung adenocarcinoma could be defined as an adenocarcinoma with tumour size less than 20 mm and the consolidation to a tumour size ratio less than 0.25, because cT1a adenocarcinomas that satisfy these criteria were diagnosed as pathologically non-invasive adenocarcinoma with a specificity of 98.7% [16] . Several researchers reported an association between maximum standardized uptake value (SUV max ) on PET-CT and the presence of pathological invasion of lung adenocarcinoma [17] [18] [19] . In a multicentre analysis, Okada et al. reported that stage 1A adenocarcinoma patients with revised SUV max 1.5 or less rarely had pathological invasion. They also suggested that these patients might be good candidates for sub-lobar resection [19] . Several recent studies reported that solid tumour size was a more important predictive factor of pathological invasiveness and prognosis than whole tumour size [20] [21] [22] . Tsutani et al. reported that the presence of pathological invasion could be predicted with considerable accuracy by the combination of solid tumour size on HRCT and SUV max on PET-CT [21] . In cases of T1b lung adenocarcinoma, patients with solid tumour size of less than 8 mm on HRCT or a SUV max of less than 1.5 on [18F]-fluoro-2-deoxy-D-glucose (FDG) PET-CT were diagnosed as pathologically non-invasive with a specificity of 98.8% [21] . Though these studies include only adenocarcinoma cases, in contrast to the present study, which includes adenocarcinoma and squamous cell carcinoma cases, based on the results of these radiological studies as well as those of the present study, patients who satisfy these radiological criteria at screening may be candidates for segmentectomy.
One of the strengths of this study was that we performed longterm follow-up with short intervals. The median follow-up period was 93.4 months, and we performed systemic work-up more than once in a year. On the other hand, this study had certain limitations. Firstly, because this study was a retrospectively analysed, smallsized and non-randomized study, there was a strong selection bias, as mentioned above. Prospective or randomized trials are required for a definitive conclusion. Secondly, this study included old cases; some of these cases were not examined by HRCT, and only a few cases were examined by PET-CT; hence, there may be differences in accuracy between old and recent cases. Thirdly, we did not have the data of surgical margins, and could not evaluate how surgical margins may have affected the oncological outcomes. Fourthly, adjuvant chemotherapy was not administered to patients who underwent segmentectomy, whereas chemotherapy was administered to 18% of the patients who underwent lobectomy. Actually, among the patients who underwent segmentectomy, there were two patients who had lymph node metastasis ; however, they refused to receive adjuvant chemotherapy. Despite these limitations, this study provided important information in selecting surgical procedures for this group of patients.
In summary, segmentectomy can be performed for cT1bN0M0 lung adenocarcinoma and squamous cell carcinoma with the same curability as lobectomy if the patients are carefully selected. We also found a possible association between oncological outcomes of surgical procedures and the presence of pathological invasion. If pathological non-invasiveness can be accurately predicted prior to surgery, we are confident that segmentectomy may be performed with the same oncological outcomes as lobectomy. As a previous study showed, cT1bN0M0 lung adenocarcinoma with a solid tumour size of less than 8 mm on HRCT or a SUV max of less than 1.5 on FDG PET-CT were considered to be pathologically non-invasive; therefore, these patients might be good candidates for segmentectomy. In addition, International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) have proposed the international multidisciplinary lung adenocarcinoma classification providing consistent terms and diagnostic criteria for adenocarcinoma subtypes [23] . This classification takes the degree of invasion as a diagnostic criterion and is reported to have a close association with clinical outcomes after surgery [24] . This may be useful in selecting candidates for segmentectomy, and so further study is needed to clarify this. Indeed, segmentectomy has many advantages over lobectomy in terms of preserving lung function and the quality of life after surgery [4, 6, 9, 25] ; hence, segmentectomy is beneficial if similar oncological outcomes are expected. However, based on previous studies and the data presented in this study, rigorous patient screening must be done to select cT1bN0M0 lung cancer patients for segmentectomy so as to achieve similar clinical benefits as with lobectomy.
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